Cargando…

Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis

OBJECTIVE: To evaluate the efficacy, immunogenicity and safety of HPV vaccination in Chinese population. METHODS: PubMed, Embase, Web of Science and Cochrane Library from inception to November 2022 were searched to collect information on clinical trials of HPV vaccines. Database search strategy used...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Jianming, Guo, Shuyan, Dong, Siping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982050/
https://www.ncbi.nlm.nih.gov/pubmed/36875363
http://dx.doi.org/10.3389/fpubh.2023.1128717
_version_ 1784900241671061504
author Guo, Jianming
Guo, Shuyan
Dong, Siping
author_facet Guo, Jianming
Guo, Shuyan
Dong, Siping
author_sort Guo, Jianming
collection PubMed
description OBJECTIVE: To evaluate the efficacy, immunogenicity and safety of HPV vaccination in Chinese population. METHODS: PubMed, Embase, Web of Science and Cochrane Library from inception to November 2022 were searched to collect information on clinical trials of HPV vaccines. Database search strategy used a combination of subject terms and free terms. Studies were first identified by two authors through reading the title, abstract and full texts and, subsequently, based on the inclusion criteria: Chinese population, with at least one of the following outcomes (efficacy, immunogenicity, and safety), and HPV vaccine RCT, those eligible were included in this paper. Efficacy, immunogenicity and safety data, pooled by random effects models, are presented as risk ratios [95% confidence intervals (CI)]. RESULTS: Eleven RCTs and four follow-up studies were included. Meta-analysis showed that HPV vaccine had good profile of efficacy and immunogenicity. The seroconversion rates were significantly higher among the vaccinated, uninfected (initial negative serum antibody) population than the placebo population for both HPV-16 (RR 29.10; 95% CI: 8.40–100.82) and HPV-18 (RR 24.15; 95% CI: 3.82–152.84), respectively. A significant reduction of the incidence of cervical intraepithelial neoplasia grade 1 (CIN1+) (RR 0.05; 95% CI: 0.01–0.23) and CIN2+ (RR 0.09; 95% CI: 0.02–0.40) was also measured. Risk for serious adverse events after HPV vaccination indicated comparable outcomes between vaccination and placebo. CONCLUSIONS: For Chinese populations, HPV vaccines enhance the level of HPV16- and HPV18-specific antibodies and reduce the incidence of CIN1+ and CIN2+ in uninfected population. Also, the risk of serious adverse events in both groups are almost equivalent. More data are needed to establish vaccine efficacy with cervical cancer.
format Online
Article
Text
id pubmed-9982050
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99820502023-03-04 Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis Guo, Jianming Guo, Shuyan Dong, Siping Front Public Health Public Health OBJECTIVE: To evaluate the efficacy, immunogenicity and safety of HPV vaccination in Chinese population. METHODS: PubMed, Embase, Web of Science and Cochrane Library from inception to November 2022 were searched to collect information on clinical trials of HPV vaccines. Database search strategy used a combination of subject terms and free terms. Studies were first identified by two authors through reading the title, abstract and full texts and, subsequently, based on the inclusion criteria: Chinese population, with at least one of the following outcomes (efficacy, immunogenicity, and safety), and HPV vaccine RCT, those eligible were included in this paper. Efficacy, immunogenicity and safety data, pooled by random effects models, are presented as risk ratios [95% confidence intervals (CI)]. RESULTS: Eleven RCTs and four follow-up studies were included. Meta-analysis showed that HPV vaccine had good profile of efficacy and immunogenicity. The seroconversion rates were significantly higher among the vaccinated, uninfected (initial negative serum antibody) population than the placebo population for both HPV-16 (RR 29.10; 95% CI: 8.40–100.82) and HPV-18 (RR 24.15; 95% CI: 3.82–152.84), respectively. A significant reduction of the incidence of cervical intraepithelial neoplasia grade 1 (CIN1+) (RR 0.05; 95% CI: 0.01–0.23) and CIN2+ (RR 0.09; 95% CI: 0.02–0.40) was also measured. Risk for serious adverse events after HPV vaccination indicated comparable outcomes between vaccination and placebo. CONCLUSIONS: For Chinese populations, HPV vaccines enhance the level of HPV16- and HPV18-specific antibodies and reduce the incidence of CIN1+ and CIN2+ in uninfected population. Also, the risk of serious adverse events in both groups are almost equivalent. More data are needed to establish vaccine efficacy with cervical cancer. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9982050/ /pubmed/36875363 http://dx.doi.org/10.3389/fpubh.2023.1128717 Text en Copyright © 2023 Guo, Guo and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Guo, Jianming
Guo, Shuyan
Dong, Siping
Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title_full Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title_fullStr Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title_full_unstemmed Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title_short Efficacy, immunogenicity and safety of HPV vaccination in Chinese population: A meta-analysis
title_sort efficacy, immunogenicity and safety of hpv vaccination in chinese population: a meta-analysis
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982050/
https://www.ncbi.nlm.nih.gov/pubmed/36875363
http://dx.doi.org/10.3389/fpubh.2023.1128717
work_keys_str_mv AT guojianming efficacyimmunogenicityandsafetyofhpvvaccinationinchinesepopulationametaanalysis
AT guoshuyan efficacyimmunogenicityandsafetyofhpvvaccinationinchinesepopulationametaanalysis
AT dongsiping efficacyimmunogenicityandsafetyofhpvvaccinationinchinesepopulationametaanalysis